Drugs / BAY2586116
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05527457 | Aug → Dec 2022 | obstructive sleep apnea syndrome | Flinders University | Completed | No outcome recorded |
| Phase 1 | NCT04872387 | May → Aug 2021 | obstructive sleep apnea syndrome | Bayer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04713826 | Mar → Aug 2021 | obstructive sleep apnea syndrome | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT04236440 | Feb 2020 → May 2021 | obstructive sleep apnea syndrome | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2586116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05527457 ↗ |
| Action | Inhibit | “a novel TASK channel blocker” NCT05527457 ↗ |
| Route | Intranasal | “160 μg BAY2586116 (nasal spray administration)” NCT04236440 ↗ |